Erik Verner - Corvus Pharmaceuticals Vice President of Chemistry Research
| CRVS Stock | USD 9.38 0.65 7.45% |
President
Dr. Erik J. Verner, Ph.D., is Vice President of Chemistry Research of the Company. Dr. Verner was Director of Chemistry for Principia Biopharma Inc., a biopharmaceutical company. Dr. Verner served as Director of Chemistry of Pharmacyclics, Inc., a biopharmaceutical company, from 2008 to February 2011, where he served as a principal scientist from 2006 to 2008. From 1996 to 2006, Dr. Verner was a principal scientist at Axys Pharmaceuticals, Inc., a biotechnology company, and Celera Corporationrationration, a subsidiary of Axys Pharmaceuticals, Inc. He was a senior scientist at Immunopharmaceutics, Inc., a biotechnology company, from 1993 to 1996 since 2015.
| Age | 59 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | 863 Mitten Road, Burlingame, CA, United States, 94010 |
| Phone | 650 900 4520 |
| Web | https://www.corvuspharma.com |
Corvus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2383) % which means that it has lost $0.2383 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4491) %, meaning that it created substantial loss on money invested by shareholders. Corvus Pharmaceuticals' management efficiency ratios could be used to measure how well Corvus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.62 in 2024. Return On Capital Employed is likely to drop to -0.63 in 2024. At this time, Corvus Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 72.5 M in 2024, whereas Other Current Assets are likely to drop slightly above 687.3 K in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| George Davis | Intel | 66 | |
| Sandra Rivera | Intel | 59 | |
| Kim Rivera | HP Inc | 50 | |
| David Inchausti | Chevron Corp | N/A | |
| Pierre Breber | Chevron Corp | 60 | |
| David Rowland | The Travelers Companies | N/A | |
| Anoop Kumar | Chevron Corp | N/A | |
| Joseph Geagea | Chevron Corp | 60 | |
| Christopher Capossela | Microsoft | 54 | |
| Claudia Lorenzo | The Coca Cola | N/A | |
| Gregory Toczydlowski | The Travelers Companies | 57 | |
| Rhonda Morris | Chevron Corp | 59 | |
| Nikolaos Koumettis | The Coca Cola | 56 | |
| Mark Randazza | The Coca Cola | 58 | |
| Kathryn Wengel | Johnson Johnson | 55 | |
| Robert Pate | Chevron Corp | 57 | |
| Maria Olivo | The Travelers Companies | 55 | |
| Tracy Keogh | HP Inc | 58 | |
| Joseph Wolk | Johnson Johnson | 54 | |
| Michelle Holthaus | Intel | 50 | |
| Jasmina Brooks | Johnson Johnson | N/A | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.24 |
Corvus Pharmaceuticals Leadership Team
Elected by the shareholders, the Corvus Pharmaceuticals' board of directors comprises two types of representatives: Corvus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Corvus. The board's role is to monitor Corvus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Corvus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Corvus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leiv Lea, Chief Officer | ||
| James MD, Senior Research | ||
| Alan Esq, Sec | ||
| MD FACP, CoFounder Director | ||
| William Jones, Vice President of Pharmaceutical Development | ||
| Erik Verner, Vice President of Chemistry Research | ||
| Jeffrey Arcara, Chief Officer | ||
| Richard MD, President, CoFounder |
Corvus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Corvus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 519.67 M | ||||
| Shares Outstanding | 64.26 M | ||||
| Shares Owned By Insiders | 4.02 % | ||||
| Shares Owned By Institutions | 44.47 % | ||||
| Number Of Shares Shorted | 2.93 M | ||||
| Price To Earning | (5.64) X | ||||
| Price To Book | 45.21 X | ||||
| EBITDA | (26.88 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.